In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva's Growth Momentum

Executive Summary

Teva has built a successful generics business by being nimble, aggressive and opportunistic, and is betting heavily that by dominating global markets it can prosper even after the end of the current spate of patent expirations. The success of its innovative drug Copaxone has given it a hedge against the volatility of generics and also changed the company in many ways. While Teva has to balance two very different businesses with limited synergies, it also must come up with a viable successor to Copaxone in order to secure its foothold in proprietary pharmaceuticals while continuing its investment in generics.
Advertisement

Related Content

Authorized Generics: Band-Aid or Strategy?
A Precarious Union: Combining Proprietary and Generic Businesses
A Precarious Union: Combining Proprietary and Generic Businesses
Teva and Ivax Bet on French Generics
Teva and Ivax Bet on French Generics
Serono's Global Ambitions
Teva's Growth Trend
Teva Ends Hoechst's Generics Misery

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel